Becton, Dickinson and Company (BDX)

In the past six months, BD reported strong Q4 2025 results with revenue up 8.3% year-over-year, though slightly below analyst estimates, and adjusted diluted EPS surpassing consensus estimates. A significant event is the planned spin-off and merger of BD's Biosciences & Diagnostic Solutions business with Waters Corporation via a Reverse Morris Trust transaction, expected to close around the end of the first quarter of calendar year 2026. Analysts anticipate BD's revenue for Q1 FY2026 to be flat year-over-year, with adjusted earnings expected around $2.81 per share. The Board of Directors declared a quarterly dividend of $1.05 per common share and authorized the repurchase of up to an additional 10 million shares. BD issued an urgent update regarding its esophagogastric balloon tamponade tubes due to safety concerns, following reports of one death and two serious injuries.

Becton, Dickinson & Co. experiences demand seasonality for its products and services, with an expected sequential decline in revenue for the first quarter of fiscal year 2026 reflecting typical seasonal patterns. The company has faced decreased demand in the Biosciences sector due to government funding cuts and a slower recovery in blood-culture testing. Challenges in the Chinese market are also expected to lead to a decline in fiscal 2026. Conversely, demand for medical devices and other healthcare products is generally high, providing resilience to the company's overall demand. The Pharmaceutical Systems business has also experienced a rapid reduction in vaccine demand.

Becton, Dickinson & Co. (BDX), also known as BD, is a multinational medical technology company specializing in the development, manufacturing, and sale of medical devices, instrument systems, and reagents. The company operates in the healthcare sector, specifically in the medical instruments and supplies industry, through three segments: BD Medical, BD Life Sciences, and BD Interventional. BDX offers medical management systems, including medication delivery and patient monitoring systems. They provide interventional medical equipment, such as surgical instruments and urological care products. BDX also offers diagnostic materials and clinical research and development tools, including automated systems for blood testing and molecular testing.

BD is a global medical technology company with a presence in virtually every country. The company's international revenue constitutes a significant portion of its total business. BD has established a strong international presence, including a European headquarters in France, a joint venture in China, a subsidiary in India, and a plant for diagnostic products in Japan.

In the past year, a notable event impacting BDX's reputation was the product safety update concerning its esophagogastric balloon tamponade tubes, which included reports of one death and two serious injuries, leading to updated instructions for healthcare professionals. Earlier, in February 2023, BD was recognized among Newsweek's 2023 list of America's Most Responsible Companies and included in the 2023 Bloomberg Gender-Equality Index.

Becton, Dickinson & Co. has a high level of institutional ownership, with 89.1% of its shares held by institutions. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., T. Rowe Price Investment Management, Inc., and State Street Corp. The Vanguard Group, Inc. is the company's largest shareholder, with approximately 9.1% ownership.